Search

Background: Hidradenitis suppurativa (HS) is a chronic inflammatory skin disorder with a significant impact on the quality of life of affected patients. This study aimed to correlate serum inflammatory markers with specific tools assessing quality of life, emotional well-being, and loneliness, such as the Dermatology Life Quality Index (DLQI), Hospital Anxiety and Depression Scale (HADS), and the UCLA Loneliness Scale. Methods: A pilot observational study including 37 patients with HS was conducted. Inflammatory serum markers, including C-reactive protein (CRP) and Erythrocyte Sedimentation Rate (ESR), were evaluated at baseline, 3 months, and 6 months later. Psychometric scores were also evaluated at the same study intervals. Results: DLQI was correlated with ESR at baseline (Spearman's rho = 0.35, p = 0.03), indicating that poorer quality of life is associated with changes in this serum marker. Disease activity, as reflected by inflammatory markers, was associated with significant psychological burden. Specifically, a worse DLQI score was associated with higher ESR (estimate β = 0.14, 95% confidence interval [CI]: 0.05–0.22; p = 0.001) and higher CRP level (estimate β = 0.25, 95% CI: 0.02–0.48; p = 0.02). Similarly, a worse UCLA score was associated with higher ESR (estimate β = 0.11, 95% CI: 0.02–0.20, p = 0.01). Conclusions: Our study results underline the close relation between systemic inflammatory markers and clinical severity together with psychological burden in HS patients, as indicated by the significant association that was revealed between ESR/CRP and poorer psychometric scores. However, further research is warranted to validate these findings. [ABSTRACT FROM AUTHOR]

Exacerbations and new onset of immune-mediated inflammatory diseases, such as psoriasis and hidradenitis suppurativa, have been reported following COVID-19 vaccination. In patients with hidradenitis suppurativa, recent studies have shown that those who received mRNA vaccines were 3.5 times as likely to develop flares following vaccination compared to patients who received non-mRNA vaccines, indicating that mRNA COVID-19 vaccines are associated with hidradenitis suppurativa flares. Similar findings have been found in other studies evaluating the association between COVID-19 vaccines and other immune-mediated inflammatory diseases such as psoriasis, atopic dermatitis, lichen planus, and alopecia areata. However, further research is warranted in larger populations to validate these findings. [ABSTRACT FROM AUTHOR]

Hidradenitis suppurativa (HS) is a chronic inflammatory cutaneous disease that often leads to decreased quality of life. Prior research assessing stress and discrimination related to stigmatization of those with HS is limited. The aim of this study was to examine the association between HS and the following factors related to psychosocial well-being: stress, discrimination, and loneliness. We performed secondary analysis of participants 18 years and older registered in the National Institutes of Health’s All of Us Research Program in March 2024. The study sample was limited to individuals who had completed ≥ 1 of 4 psychosocial well-being surveys. Among 1,352 individuals with HS, 135 were included in the sample. Among 208,290 individuals without HS, 56,902 were included. The following surveys assessed loneliness, stress, perceived discrimination in everyday settings, and perceived discrimination in medical settings, respectively: the UCLA Loneliness Scale, Cohen Perceived Stress Scale, Everyday Discrimination Scale, and Discrimination in Medical Settings Scale. The association between HS and survey scores was modeled using multivariable linear regression adjusted for self-reported sex, self-reported race and ethnicity, age, and income. In an unadjusted model, those with HS reported a significantly higher degree of stress (MeanHS (SD) = 21.5 (4.74); Meannon−HS (SD) = 19.8 (3.98); p < 0.001), discrimination in everyday settings (MeanHS (SD) = 18.9 (8.16); Meannon−HS (SD) = 16.0 (7.06); p < 0.0001), and discrimination in healthcare settings (MeanHS (SD) = 1.77 (0.64); Meannon−HS (SD) = 1.56 (0.62); p < 0.001). After adjusting for sex, race, age, and income, the association between HS and discrimination in healthcare settings was non-significant; however, associations between HS and increased levels of perceived stress and everyday discrimination remained significant. Low survey completion rates and demographic differences between those who did and did not complete the study surveys may limit generalizability of results. Findings suggest that those with HS may benefit from regular screening for psychosocial well-being and provision of support resources. [ABSTRACT FROM AUTHOR]

Hidradenitis suppurativa (HS) is a painful, chronic inflammatory skin condition. Patients experience exacerbations, leading them to present to the emergency department (ED) for incision and drainage. Direct injection of local anesthetic into these lesions is extremely painful and seldom provides adequate anesthesia. A modified method of the PECS II block can provide anesthesia to the skin of the axilla, making management of HS much less painful for the patient. We performed a bilateral modified PECS II block on a patient requiring incision and drainage of HS lesions in both axillae. She subsequently required no local anesthetic for the procedure. The second injection of the traditional PECS II block involves the deposition of anesthetic in the fascial plane between the pectoralis minor muscle and the serratus anterior muscles. This injection targets the lateral branch of the intercostal nerves, which provide sensory innervation to the axilla. A modified technique of the PECS II block, in which only the second injection is performed, is a potentially effective method for anesthetizing the axilla of patients with HS prior to incision and drainage. [ABSTRACT FROM AUTHOR]

Introduction: Hidradenitis suppurativa (HS) is a chronic skin disease that significantly reduces the quality of life of patients, especially affecting the intimate areas. Surgical treatment is one of the tools available for treating HS, which can significantly improve patients' quality of life. Aim: To evaluate the surgical treatment of 31 patients treated surgically at the Centre for Burns Treatment in Siemianowice Śląskie, with a follow-up of 6 months. Material and methods: Thirty-one HS patients were operated on with classical reconstructive methods. The patients were followed up for 6 months in the outpatient clinic. We gathered clinical data of 31 post-operative patients and statistical analysis was performed. Results: 83.87% of the patients were completely healed. The study showed that HS recurrence in the surgical site occurred in 1 (3.23%) patient only after 6 months of follow-up. We found a statistically significant (p < 0.050) positive correlation between patients' age and body mass index (BMI), disease duration and time of diagnosis. BMI value additionally correlated with disease duration and time of diagnosis, while disease duration correlated with time of diagnosis. Conclusions: Surgical treatment is an effective method in HS. The relatively low recurrence rate after 6 months and, in most patients, full healing, support the good therapeutic effect of surgical treatment. [ABSTRACT FROM AUTHOR]

Background: The most frequent inflammatory skin diseases are psoriasis, atopic dermatitis, hidradenitis suppurativa, and acne. Their management is challenging for dermatologists since their relapsing chronic clinical course is associated with a great impact on quality of life. Nevertheless, the recent introduction of novel therapies, such as biological drugs and small molecules has been changing the history of these diseases. Methods: A systematic review of the scientific literature of case reports, case series, epidemiological studies, reviews, and systematic reviews regarding teledermatology and inflammatory skin disease. Studies were identified, screened, and extracted for relevant data following the PRISMA (preferred reporting items for systematic reviews and meta-analyses) guidelines. Results: A total of 69 cases articles were included in the review. Conclusions: As we have shown in the review, several experiences of teledermatology for patients affected by inflammatory skin diseases have been demonstrated to increase due to clinical access to hospital and specialized health care services, allowing better access to specialized dermatology care for people living in remote areas, and saving costs and money with health care. [ABSTRACT FROM AUTHOR]

Hidradenitis suppurativa (HS) is a chronic inflammatory disease with a challenging treatment. Current guidelines reserve dapsone as a third line agent for patients with mild to moderate HS. To our knowledge, only four small case series have been reported. The objective of this study was to assess the effectiveness and safety of dapsone in our clinical practice. A retrospective observational single‐center study of 56 HS patients who underwent treatment with dapsone from May 1, 2015, to June 1, 2021, was performed. The Hidradenitis Suppurativa Clinical Response (HiSCR) scale was used to evaluate the response to treatment. Fifty‐six patients were included, 66% of which were men, with a median age of 33 years. Most of them had mild or moderate disease and belonged to LC2 follicular phenotype. All patients had been refractory to first‐line treatments. Dapsone was prescribed at doses of 50–150 mg/day. 62.5% of the patients achieved HiSCR after 12 weeks of treatment. No serious adverse reactions were detected. The median duration of treatment was 8 months. After multivariate analysis, an association was found between the presence of fistulous tracts and the risk of non‐response to the drug. In four of the dapsone responders, oral retinoids were added to achieve a sustained response. Limitations include the retrospective and non‐controlled nature of this study. In conclusion, dapsone is an effective and well‐tolerated option for long‐term HS treatment, and in this series, it was mainly chosen for patients with LC2 phenotype. It would be interesting to study combination with retinoids and other management options. [ABSTRACT FROM AUTHOR]

Zero of nine patients given <2 mg/m SP 2 sp BID of omacetaxine developed rash, but rash occurred in six of 10 patients receiving 2 mg/m SP 2 sp BID, and in both patients receiving 3 mg/m SP 2 sp BID. As apoptosis was prominent, cFLIP expression was examined in patient skin biopsies and a cell line treated with the component drugs of the AML-02 regimen. [Extracted from the article]

Patients with certain inflammatory skin diseases have multiple risk factors for venous thromboembolism (VTE). The objective of the study was to determine whether atopic dermatitis (AD), psoriasis, pemphigus, pemphigoid and/or hidradenitis is associated with VTE in US adults. Data were analyzed from the 2002–2012 Nationwide Inpatient Sample, a representative cohort of US hospitalizations (N = 72,512,581 adults, including 1,389,292 with VTE). In multivariable logistic regression models including age, sex, insurance, household income and race/ethnicity, hospitalization for AD (adjusted odds ratio [95% confidence intervals] 1.22 [1.17–1.27]), pemphigus (1.96 [1.68–2.28]) and pemphigoid (1.64 [1.47–1.83]) was associated with VTE. These associations remained significant in virtually all patient subsets, including males and females, different age groups and those with and without long-term corticosteroid use. In particular, AD, pemphigus and pemphigoid were each associated with DVT and PE. VTE was associated with increased inpatient length of stay, cost of care and mortality across all the inflammatory skin diseases. HS and psoriasis were not consistently associated with VTE. AD, pemphigus and pemphigoid and some subsets of patients with HS were associated with higher odds of hospitalization for VTE. Patients with these inflammatory skin diseases may benefit from increased screening and prevention of VTE. [ABSTRACT FROM AUTHOR]

Keywords: alopecia areata; eczema; hidradenitis; psoriasis; vitiligo EN alopecia areata eczema hidradenitis psoriasis vitiligo 928 930 3 06/08/22 20220601 NES 220601 Understanding the needs and emotions of patients is the first step for any physician treating a patient. Notably, patients with alopecia areata reported stress more frequently than patients with the other five dermatoses. [Extracted from the article]

Erectile dysfunction, hidradenitis, immunotherapy, lymphedema, scrotum, surgery Keywords: erectile dysfunction; hidradenitis; immunotherapy; lymphedema; scrotum; surgery EN erectile dysfunction hidradenitis immunotherapy lymphedema scrotum surgery e184 e186 3 05/20/22 20220501 NES 220501 Hidradenitis suppurativa (HS) involving the anogenital and inguinal regions can cause considerable morbidity. Persistent poorly controlled HS results in diffuse scarring, fibrosis and lymphoedema that can impact micturition, social and sexual functioning.2 Tumour necrosis factor-alpha inhibitors, namely adalimumab, have significantly improved the management of severe HS. [Extracted from the article]

Oral and topical zinc have been used for the treatment of acne, but there is a lack of definitive evidence for their efficacy. (a) To determine if mean serum zinc levels differ between acne patients and controls and (b) to determine the efficacy of zinc preparations in the treatment of acne. A systematic review and meta‐analysis was performed according to recommended PRISMA [Preferred Reporting Items for Systematic Reviews and Meta‐Analyses] guidelines. Subjects with acne had significantly lower serum zinc levels compared to controls. Patients who were treated with zinc had a significant improvement in mean inflammatory papule count compared to those who were not treated with zinc. There was no significant difference in the incidence of side effects in zinc supplementation vs comparators. Acne patients have decreased serum zinc levels. Zinc is effective for the treatment of acne, particularly at decreasing the number of inflammatory papules, when used as monotherapy or as an adjunctive treatment. [ABSTRACT FROM AUTHOR]

Background/Objectives: Hidradenitis suppurativa is a chronic, painful, debilitating disease that may present in the pediatric years. Overweight and obesity are believed to worsen disease severity, but many patients do not receive counseling regarding weight control. The objective of this study is to examine the percentage of hidradenitis suppurativa patients who receive weight counseling as a part of their disease management and which specialties primarily care for these patients. Methods: We performed a retrospective chart review of pediatric hidradenitis suppurativa patients between January 2011 and October 2018. Demographic data, height, weight, body mass index, body mass index percentiles, number of visits per department, referrals to the Center for Healthy Weight and Nutrition, and referring provider department data were collected. Results: A total of 535 pediatric hidradenitis suppurativa patients were reviewed; 79.6% were female, and the mean age at diagnosis was 14.5 years. 11.6% of patients were overweight, and 54.2% were obese. 32.1% of overweight and obese hidradenitis suppurativa patients received a referral to the Center for Healthy Weight and Nutrition. The majority of referrals were placed by Primary Care. Dermatology placed 7.1% of the referrals to the Center for Healthy Weight and Nutrition for these patients. Conclusions: The results suggest that there is a need for increased awareness, education, and counseling on weight management and nutrition for pediatric hidradenitis suppurativa patients. Further studies are needed to determine the success of counseling on weight control and disease severity. [ABSTRACT FROM AUTHOR]

The article describes the case of a 24-year-old female patient who presented with asymptomatic red papules and pustules on the upper body. Prior consultation, she used topical steroids and topical antibiotics based on the advice of a doctor. The patient was receiving azathioprine treatment for Crohn's disease. Histopathology findings pointed to the diagnosis of neutrophilic eccrine hidradenitis. The lesions improved with postinflammatory hyperpigmentation and with oral azithromycin therapy.

Background and Design: Hidradenitis suppurativa (HS) is a painful, chronic, inflammatory skin disease and there is no effective standard method for its treatment. The studies on the successful results of adalimumab in the treatment of HS are increasing and its use is approved by the Ministry of Health in our country. Materials and Methods: The efficacy and side effects of adalimumab were evaluated retrospectively in 9 patients who were diagnosed with resistant HS. Adalimumab was administered 40 mg subcutaneously per week. Patients were followed closely for infections and other side effects. In patients, nodules, abscesses and fistulas were determined at the beginning of the treatment, at the 4th and 12th week of the treatment. The values of global pain scores, life quality index scores and C-reactive protein levels recorded at the beginning and at the 12*h week of the treatment were evaluated. Results: The ages of 9 patients receiving adalimumab for severe HS were between 33-67 (mean: 50.6), and 7 of the patients were male. The disease duration ranged from 2 to 25 years (mean: 13 years) 5 of the patients according to the Hurley classification was determined as stage 2 and 4 as stage 3. In the 12*h week, the number of nodules, abscess and draining fistulas were decreased respectively 60.2%, 69.3% and 52.1%. C-reactive protein levels of 16.3 mg/L at the beginning of treatment were 5.5 mg/L at 12 weeks. Before the treatment, life quality index score was 23.4, and after 12 weeks, the score decreased to 6.8. There was a significant improvement in the quality of life. Pain scores of 6.6±3.4 before the treatment were reduced to 1.5±2.5 in the 12*h week of treatment. No side effects were observed during treatment. Coclusion: In this study, adalimumab was evaluated as an effective and well tolerated treatment option in moderate and severe HS. [ABSTRACT FROM AUTHOR]

Objective: Hidradenitis suppurativa (HS) is a chronic, recurrent inflammatory skin disease. Our aim of this study is to review the demographic, clinical characteristics, treatment options of the patients who were being followed up with diagnosis of HS in our hospital during the last 9 years and to make a comparison with the data from other countries. Material and Methods: A total of 59 patients with HS diagnosed in our Dermatology Department between 2010-2019 were evaluated retrospectively. Results: Seventeen (28.8%) of 59 patients were female, 42 (71.2%) were male. The mean age at diagnosis was 31.05±1.61 (minimum / maximum: 14-60). Seventeen patients (28.8%) had stage 1, 26 patients (44.1%) had stage 2 and 16 patients (27.1%) had stage 3 disease. Axilla was the most affected area. Topical agents (topical clindamycin, antiseptic solutions) and oral antibiotics (doxycycline, ciprof loxacin, ampicillin-sulbactam, amoxicillin-clavulanic acid) were the most commonly used treatment options. Treatment resistant eight patients were treated with a biological agent adalimumab. Conclusion: In literature, there are few epidemiological studies related to HS in Turkey. The clinical, demographic and therapeutic data of 59 HS cases in our clinic were summarized. However, we believe that multi-center studies conducted with larger number of patients are needed in order to reach more comprehensive data on this subject. [ABSTRACT FROM AUTHOR]

Hidradenitis suppurativa is a chronic relapsing disease with multiple abscesses, nodules, and scars in the apocrine bearing areas. Dowling-Degos is a rare autosomal dominant genodermatosis characterized by multiple hyperpigmented macules or papules in reticulate pattern, affecting mainly the flexures. We report a case of coexisting hidradenitis suppurativa and Dowling-Degos disease in a 31-year-old male in whom PSENEN mutation analysis revealed a splice site mutation c.62-1G>T. [ABSTRACT FROM AUTHOR]

Summary: Background: Despite the heavy purulence observed in hidradenitis suppurativa (HS), the kinetics of complement anaphylatoxins acting to prime chemotaxis of neutrophils has not been studied. Objectives: To explore complement activation in HS. Methods: Circulating concentrations of complement factor C5a, as well as of membrane attack complex C5b‐9, were determined in the plasma of 54 treatment‐naïve patients and of 14 healthy controls, as well as in the pus of seven patients. Results were correlated with Hurley stage and International Hidradenitis Suppurativa Severity Score. Peripheral blood mononuclear cells (PBMCs) were isolated from seven patients with Hurley stage III HS and seven healthy volunteers and stimulated in the presence of 25% of plasma for the production of tumour necrosis factor‐α (TNF‐α). Results: Circulating C5a and C5b‐9 were significantly greater in patient than in control plasma; however, concentrations in pus were very low. Circulating C5a levels exceeding 28 ng mL−1 were associated with a specificity > 90% with the occurrence of HS. Circulating levels of C5a and C5b‐9 were greater in patients with more severe HS. PBMCs of patients produced high concentrations of TNF‐α only when growth medium was enriched with patient plasma; this was reversed with the addition of the C5a blocker IFX‐1. Conclusions: Systemic complement activation occurs in HS and may be used as a surrogate biomarker of HS. C5a stimulates overproduction of TNF‐α and may be a future therapeutic target. [ABSTRACT FROM AUTHOR]

Abstract: Background/Objectives: Lymphocytic hidradenitis is a non‐specific histopathological feature observed in many dermatoses such as lupus erythematosus, morphea or scleroderma. When it occurs it is usually accompanied by the other distinctive histological features of those conditions. Isolated lymphocytic hidradenitis is uncommon and its clinical features and associated underlying medical conditions are still undetermined. Methods: We performed a retrospective review of patients who clinically presented with annular erythema between 2000 and 2016. Altogether, 30 patients with a histopathological presentation of isolated lymphocytic hidradenitis were identified. Their following characteristics were recorded: clinical features, number and localisation of lesions, serology and other associated medical conditions. Results: Isolated lymphocytic hidradenitis was found most frequently in middle‐aged women. Most patients (n = 28, 93%) presented with many annular erythematous patches and plaques with mild pruritus; 22 (73%) had the SS‐A antibody and 17 (57%) met the diagnostic criteria of Sjögren syndrome. Among these patients, 11 had primary and six had secondary Sjögren syndrome associated with systemic lupus erythematosus. Altogether 15 (50%) patients tested positive for a high titre of the antinuclear autoantibody. Other underlying diseases identified during the follow‐up period include cryoglobulinaemia, angioimmunoblastic T‐cell lymphoma, autoimmune hepatitis, hepatitis C infection and toxic thyroid goitre. Conclusions: Lymphocytic hidradenitis is a microscopic finding associated with annular erythemas of Sjögren syndrome. Systemic survey for sicca symptoms and work up for autoimmune diseases, including antinuclear antibodies, SS‐A, SS‐B antibodies, cryoglobulin, lymphoma, viral and autoimmune hepatitis should be performed to facilitate the correct diagnosis. [ABSTRACT FROM AUTHOR]

Summary Introduction There is no reference available concerning the standard healing time based on dermatological diseases responsible for cutaneous substance losses. The aim of our study was to assess the healing time after surgical debridement of necrotizing fasciitis (NF), hidradenitis suppurativa (HS) and skin necrosis due to trauma (SNT) based on multiples existing co-morbidities among these patients to provide surgeons with accurate scientific data in order to inform and educate patients and nurses who are practicing care under the supervision of the surgeon. Materials and methods This was a retrospective study. The primary endpoint was the time for complete wound healing, which was calculated from the time of the last surgical procedure to the complete wound healing corresponding to the time of complete reepithelialization, when daily dressings were no longer needed. Results A total of 107 patients were included. The mean time for complete wound healing was 64.94 ± 31.55 days in patients with NF, 45.70 ± 21.40 days in patients with SNT and 75.02 ± 26.41 days in patients with HS (SNT versus NF, P = 0.004** and SNT versus HS, P < 0.0001**). Conclusion The mean time for complete wound healing was 64.94 days in patients with NF, 45.70 days in patients with SNT, 75.02 days in patients with HS. This study can be considered as a referential based on the experience of a reference centre for these 3 pathologies (NF, HS, and SNT) whose aim is to inform plastic surgeons in order to anticipate the management or educate the patient. [ABSTRACT FROM AUTHOR]

Abstract: Background: Although recent hidradenitis suppurativa studies have shown that early‐onset disease is associated with a positive family history and more widespread disease, research in pediatric hidradenitis suppurativa is limited. Methods: Thirty‐three children diagnosed with hidradenitis suppurativa during an 18‐month period were included in this institutional review board–approved, retrospective chart review. Information on demographic characteristic, family history, and timing of onset (prepubescent vs postpubescent) was extracted. The Fisher exact test, Cochran‐Armitage exact trend test, and chi‐square test were used to examine the association between prepubescent or postpubescent onset of hidradenitis suppurativa and sex, disease severity, and family history. Results: A significantly higher percentage of patients with postpubescent onset were female (85.7%) than male (14.3%), whereas those with prepubescent onset were more likely to be male (58.3%) than female (41.7%; P = .02). Associations between disease onset and positive family history of hidradenitis suppurativa (P = .47) or higher Hurley stage of disease (P = .15) were not statistically significant. Conclusion: Boys are more likely to have prepubescent onset of hidradenitis suppurativa and girls to have postpubescent onset. This shift in sex distribution is unexplained, but we hypothesize that, whereas the role of ovarian hormones in the pathogenesis of HS may underlie much of adult‐onset disease, it is less important in prepubescent disease. [ABSTRACT FROM AUTHOR]

Anti-drug antibody formation occurs with most biological agents across disease states, but the mechanism by which they are formed is unknown. The formation of anti-drug antibodies to adalimumab (AAA) may decrease its therapeutic effects in some patients. HLA alleles have been reported to be associated with autoantibody formation against interferons and other TNF inhibitors, but not adalimumab. We analyzed samples from 634 subjects with either rheumatoid arthritis (RA) or hidradenitis suppurativa (HS): 37 subjects (17 RA and 20 HS) developed AAA (AAA+) during adalimumab treatment and 597 subjects (348 RA, 249 HS) did not develop AAA (AAA-) during the clinical trials. Using next-generation sequencing-based HLA typing, we identified three protective HLA alleles (HLA-DQB1*05, HLA-DRB1*01,and HLA-DRB1*07) that were less prevalent in AAA+ than AAA–subjects (ORs: 0.4, 0.25 and 0.28, respectively; and P values: 0.012, 0.012 and 0.018, respectively) and two risk HLA alleles (HLA-DRB1*03 and HLA-DRB1*011) that were more abundant in AAA+ than AAA–subjects (ORs: 2.52, and 2.64, respectively; and P values: 0.006 and 0.019). Similar to the finding of Billiet et al. who found that carriage of the HLA-DRB1*03 allele was more prevalent in those with anti-infliximab antibodies (OR = 3.6, p = 0.002, 95% CI: [1.5,8.6]).), we found HLA-DRB1*03 allele was also more prevalent in anti-adalimumab positive (OR = 2.52, p = 0.006, 95% CI: [1.37,4.63]). The results suggest that specific HLA alleles may play a key role in developing AAAs in RA and HS patients treated with adalimumab. [ABSTRACT FROM AUTHOR]

Summary: Background: Patients with hidradenitis suppurativa (HS) often report opportunistic infections such as herpes and urinary tract infections. Aim: To compare opportunistic infections in patients with HS against a group of healthy controls (HCs). Methods: In total, 99 patients with HS and 109 HCs were recruited at random to this retrospective case–control study. We devised a questionnaire to explore the frequency of minor infections, general practitioner (GP) visits and sick days experienced during the past 6 months. Additionally, participants were asked if they felt unwell more often compared with their peers. Results: Patients with HS felt unwell more often than did HCs (26.3% vs. 7.3%, P < 0.001). Although there was no difference between the groups in five of the seven diseases studied, patients with HS had a higher frequency of the common cold (P < 0.01) and genital herpes (P < 0.01). Number of pack‐years of smoking did not affect risk of infections (Pearson correlation, P = 0.51). Subgroup analysis of nonsmokers found the same differences in frequency of minor infections, common cold and genital herpes between patients with HS and controls. Conclusions: Patients with HS appear to experience more frequently symptoms compatible with minor infections in general, and the common cold and genital herpes specifically. This results in more GP visits and more sick days. Further research is needed to determine if this is caused by an immunological hyper‐reactive state in these patients or a reduced threshold for minor infections. [ABSTRACT FROM AUTHOR]

Abstract: Background: Surgery is an important treatment modality for hidradenitis suppurativa (HS). Various methods of HS surgery have been described. Even though wide excision is a common surgical procedure for HS, data on the recurrence rate and patient satisfaction are scarce. Objective: To determine the recurrence rate and patient satisfaction of HS lesional wide excision (complete excision) with secondary intention healing. Methods: A single centre retrospective study. Hundred and twenty eligible patients were identified from our medical files, and an individualized questionnaire was sent. Results: Eighty‐six patents responded to our questionnaire (71.7%). Of whom, 84 patients underwent in total 253 procedures. The mean follow‐up time per procedure was 36.2 months. In 37.6% of the procedures, recurrence occurred within a mean follow‐up period of 3 years (after a median of 6.0 months). Total remission of an anatomical area was achieved in 49% of the procedures, whereas natural disease progression occurred in 13%. The genital region was the most prone to recurrence. The majority of the patients were glad that they had undergone the procedure and would recommend the surgical procedure to other HS patients. Conclusion: Lesional wide excision (complete excision) with secondary intention healing yields a meaningful local cure rate for HS and is well tolerated. [ABSTRACT FROM AUTHOR]

Background: Malodourous discharge in patients with hidradenitis suppurativa (HS) has a strong psychosocial impact and is often reported as a source of embarrassment, low self-esteem, social stigma, and barriers to interpersonal relationships. Malodour is a maker of bacterial colonization, and its role in HS is understudied. Objectives: The aim of this study is to assess the relationship between severity of malodourous discharge and quality-of-life impairment in patients with HS. Methods: This is a cross-sectional study of 51 patients recruited from the Women's College Hospital and the York Dermatology Centre. Quality of life was assessed using both the Dermatology Life Quality Index (DLQI) and the Skindex-29 instruments. Results: Severity of odour significantly predicts the total Skindex score after controlling for disease severity as measured by the Hurley stage and Sartorius score (R2 = 0.39, F = 8.11, P < .0001). However, odour severity is not a predictor of DLQI (R2 = 0.17, F = 2.63, P = .064). There was no difference in mean DLQI scores for the low- vs high-odour groups, but patients with high odour had a greater quality of life impairment as measured by the Skindex tool (t = -4.19, df = 43, P < .0001, mean difference = -18.87). Conclusion: Malodour is a common symptom that significantly impairs quality of life in patients with HS. The fact that this effect is captured in Skindex and not the DLQI may be attributed to the nonspecificity of the DLQI in terms of unique disease characteristics. It is important to address odour in the management of patients with HS. [ABSTRACT FROM AUTHOR]

Objectives: Hidradenitis suppurativa is seen as a result of the occlusion, constriction and bacterial infection of the apocrine glands in bilateral axillas, submammarian areas, neck, inguinal regions, flexural surfaces of the thighs and anogenital areas. Among the biological agents adalimumab is a recombinant human IgG1 monoclonal antibody; TNF-a antagonist approved to be used in the treatment of hidradenitissuppurativa. Methods: In this study, 12 patients resistant to conventional treatments with moderate severity, Hurley stage 2 or 3 were started subcutaneous adalimumab treatment. The disease activities upon the hidradenitis suppurativa, clinical severity index and life quality index of the patients were examined both before and 1 year after the treatment. Results: Twelve patients were recruited. In the examination of the hidradenitis suppurativa clinical severity scores, significant clinical responses were noted in 9 (75%) patients. While the mean value of the life quality index was 14.4±6.9 before the treatment, it was determined to be significantly decreased to 4.3±3.8 after the treatment. Conclusion: We concluded that adalimumab; the unique biological agent approved to be used in the treatment of treatment-resistant, moderate-severe hidradenitis suppurativa is efficient and safe in similar ratios with the previous clinical studies in the literature. [ABSTRACT FROM AUTHOR]

Neutrophilic eccrine hidradenitis ( NEH) is a rare neutrophilic dermatosis, first described in patients undergoing chemotherapy for a malignant haemopathy. It has polymorphous clinical features and the association of both clinical and histological features is necessary to make a diagnosis. We report the first two cases of NEH in patients treated with a BRAF inhibitor ( BRAFi), either dabrafenib or vemurafenib, for a stage IV metastatic melanoma. Disseminated erythematous plaques associated with fever and polyarthralgia occurred early after the initiation of treatment and were badly tolerated. Histological analyses confirmed the diagnosis of NEH. Symptoms disappeared a few days after the cessation of treatment and introduction of topical steroids. The replacement of one BRAFi with another is a therapeutic alternative as it is not necessarily associated with a relapse of NEH. NEH can be added to the spectrum of neutrophilic dermatoses induced by BRAFis. It occurs earlier (3-4 days) than previously described drug-induced NEH (9-12 days) and may be an earlier stage of eccrine squamous syringometaplasia, which has already been reported in the context of BRAFi-treated patients. [ABSTRACT FROM AUTHOR]

Background:Obesity continues to increase in the United States (US) and elsewhere, with a number of published dermatologic associations. The purpose of this study was to characterize obesity among US office visits for dermatologic diseases. Methods:Data from the 2005 to 2011 National Ambulatory Medical Care Survey (NAMCS) and National Hospital Ambulatory Medical Care Survey (NHAMCS) were searched for the most common dermatologic diagnoses for which body mass index (BMI) could be classified. Results:For all dermatologic patient visits, 10% were underweight, 36.5% were normal weight, 23.8% were overweight and 29.7% were obese. Increasing age predicted the yearly increased likelihood of obesity (OR 1.02; 95% CI 1.01, 1.02;p < 0.0001). Logistic regression controlling for age, sex, race and dataset found that in addition to age, NHAMCS dermatologic diagnosis patients were more likely to be obese than NAMCS patients (OR 1.22; 95% CI 1.03, 1.45;p = 0.02). Specific diseases were found to have the highest obesity rates, including psoriasis, hidradenitis suppurativa and acanthosis nigricans. Conclusion:A large proportion of dermatologic diagnosis patients are obese, and awareness could lead to interventions that may improve their disease and decrease risks of comorbidities. [ABSTRACT FROM PUBLISHER]

Background: Hidradenitis suppurativa (HS) is a debilitating dermatologic condition presenting with recurrent abscesses. While there are multiple scales to determine HS severity, none are designed for self-administration. A validated severity self-assessment tool may facilitate survey research and improve communication by allowing patients to objectively report their HS severity between clinic visits. Objectives: The purpose of this study was to assess a self-administered HS measure. Methods: An HS self-assessment tool (HSSA) with 10 photographs of different Hurley stages was developed. The tool was administered to patients diagnosed with HS who visited the Wake Forest Baptist Health dermatology clinic over a span of 2 months. Physician-administered Hurley stage was recorded to determine criterion validity. To assess test-retest reliability of the measure, patients completed the HSSA again at least 30 minutes after the first completion. Results: Twenty-four patients completed the measure, and 20 of these patients completed it twice. Agreement between physician-determined Hurley stage and self-determined Hurley stage was 66.7% with a weighted kappa of 0.57 (95% confidence interval [CI]: 0.30-0.84). The weighted kappa for agreement between patients' initial and second completion of the HSSA was 0.81 (95% CI: 0.64-0.99). Conclusions: The self-administered measure provides moderate agreement with physician-determined Hurley stage and good test-retest reliability. [ABSTRACT FROM AUTHOR]

BACKGROUND Hidradenitis suppurativa is a progressive, recurrent inflammatory disease. Surgical management is potentially curative with limited efficacy data. OBJECTIVE To evaluate hidradenitis surgical patients. METHODS Retrospective review of outcomes of 590 consecutive surgically treated patients. RESULTS Most patients were white (91.0% [435/478]), men (337 [57.1%]), smokers (57.7% [297/515]) with Hurley Stage III disease (476 [80.7%]). Procedure types were excision (405 [68.6%]), unroofing (168 [28.5%]), and drainage (17 [2.9%]) treating disease of perianal/perineum (294 [49.8%]), axilla (124 [21.0%]), gluteal cleft (76 [12.9%]), inframammary (12 [2.0%]), and multiple surgical sites (84 [14.2%]). Postoperative complications occurred in 15 patients (2.5%) and one-fourth (144 [24.4%]) suffered postoperative recurrence, which necessitated reoperation in one-tenth (69 [11.7%]) of patients. Recurrence risk was increased by younger age (hazard ratio [HR], 0.8; 95% confidence interval [CI], 0.7-0.9),multiple surgical sites (HR, 1.6; 95% CI, 1.1-2.5), and drainage-type procedures (HR, 3.5; 95% CI, 1.2-10.7). Operative location, disease severity, gender, and operative extent did not influence recurrence rate. CONCLUSION Excision and unroofing procedures were effective treatments with infrequent complications and low recurrence rates. Well-planned surgical treatment aiming to remove or unroof the area of intractable hidradenitis suppurativa was highly effective in the management of this challenging disease. [ABSTRACT FROM AUTHOR]

More than 50 interventions have been used to treat hidradenitis suppurativa ( HS), and so therapy decisions can be challenging. Our objective was to summarize and appraise randomized controlled trial ( RCT) evidence for HS interventions in adults. Searches were conducted in Medline, Embase, CENTRAL, LILACS, five trials registers and abstracts from eight dermatology conferences until 13 August 2015. Two review authors independently assessed study eligibility, extracted data and assessed methodological quality. Primary outcomes were quality of life and adverse effects of the interventions. Twelve trials, from 1983 to 2015, investigating 15 different interventions met our inclusion criteria. The median trial duration was 16 weeks and the median number of participants was 27. Adalimumab 40 mg weekly improved the Dermatology Life Quality Index ( DLQI) by 4·0 points, which equates to the minimal clinically important difference for the scale, compared with placebo (95% confidence interval −6·5 to −1·5 points). Evidence quality was reduced to 'moderate' because the results are based on only a single study. Adalimumab 40 mg every other week was ineffective in a meta-analysis of two studies comprising 124 participants. Infliximab 5 mg kg−1 improved the DLQI score by 8·4 points after 8 weeks in a moderate-quality study completed by 33 of 38 participants. Etanercept 50 mg twice weekly was ineffective. Inclusion of a gentamicin sponge prior to primary closure did not improve outcomes. Other interventions, including topical and oral antibiotics, were investigated by relatively small studies, preventing treatment recommendations due to imprecision. More, larger RCTs are required to investigate most HS interventions, particularly oral treatments and surgical therapy. Moderate-quality evidence suggests that adalimumab given weekly and infliximab are effective, whereas adalimumab every other week is ineffective. [ABSTRACT FROM AUTHOR]

Background Treatment of hidradenitis suppurativa ( HS) is difficult and the search for effective therapies continues. Objectives To evaluate the efficacy of ustekinumab and to discover a potential biomarker for HS. Methods Seventeen patients were included in this open-label study and treated with 45 or 90 mg ustekinumab at weeks 0, 4, 16 and 28. Proteomic technology and enzyme-linked assay analysis was applied to sera. Results Twelve patients completed the protocol. Moderate-to-marked improvement of the modified Sartorius score was achieved in 82% of patients at week 40 and the Hidradenitis Suppurativa Clinical Response 50 in 47%. With regard to the expression of 54 serum proteins, at baseline, a significant difference was observed between patients and healthy controls. Involved pathways were related to inflammation, immune cell signalling and tissue morphology/development. Good responders had milder disease and lower expression of leukotriene A4-hydrolase ( LTA4H). Interleukin ( IL)-2R, tumour necrosis factor-α, IL-17A and IL-17F were not elevated and did not change during treatment. Conclusions The majority of patients improved with ustekinumab. Although no biomarker was discovered, low LTA4H concentrations with mild disease severity may be predictive of the effectiveness of ustekinumab. [ABSTRACT FROM AUTHOR]

Abstracts submitted during the joint Canadian Hidradenitis Suppurativa Foundation (CHSF)/Hidradenitis Suppurativa Foundation Inc. (HSF)/European Hidradenitis Suppurativa Foundation e.V (EHSF) pre-World Congress of Dermatology Hidradenitis Suppurativa Symposium in June 2015 are presented including "Epidemiology and the Burden of the Disease," "An Update on Pathophysiology" and "Factors Associated With Hidradenitis Suppurative Severity."

Hidradenitis suppurativa (HS) is a chronic, inflammatory, debilitating skin disease. The aim of the study was to systematically review the literature and critically answer the question: In patients with HS, do cardiovascular risk factors appear at a significantly higher rate compared with controls? The main search was conducted in Medline, Embase and the Cochrane Central Register. Studies eligible for inclusion were of case-control, cross-sectional and cohort design, and included comparison of any cardiovascular risk factor(s) in patients with HS with those of control groups. An I² value > 50% was considered to show substantial heterogeneity. In this case, DerSimonian and Laird random-effect models were considered to compute pooled odds ratios (OR). Otherwise, a fixed-effects model was suitable. Nine studies, with 6174 patients with HS and 24 993 controls, were included. Significant association of HS with obesity [OR 3.45, 95% confidence interval (CI) 2.20-5.38, P < 0.001], central obesity (OR 2.97, 95% CI 1.41-6.25, P = 0.004), active smoking (OR 4.34, 95% CI 2.48-7.60, P < 0.001), history of smoking (OR 6.34, 95% CI 2.41- 16.68, P < 0.001), hypertriglyceridemia (OR 1.67, 95% CI 1.14-2.47, P = 0.009), low high-density lipoprotein (HDL) (OR 2.48, 95% CI 1.49- 4.16, P < 0.001), diabetes (OR 2.85, 95% CI 1.34-6.08, P = 0.007) and metabolic syndrome (OR 2.22, 95% CI 1.62-3.06, P < 0.001) was detected. Associations were significant both in population and hospital patients with HS, with hospital HS groups having uniformly higher ORs than the population HS groups. Causality could not be assessed. Heterogeneity was substantial in all analyses. This systematic review indicated that cardiovascular risk factors appear at a significantly higher rate in patients with HS compared with controls. The need for screening of patients with HS for modifiable cardiovascular risks is emphasized. [ABSTRACT FROM AUTHOR]

The article discusses the case of an 8 year old Caucasian girl whose lesions started at the age of 6 as painful nodules in the groins prior to any signs of puberty. Examination showed few polyporous comedones, red papules and atrophic scars in the inguinal regions and a diagnosis of hidradenitis suppurative was made based on the characteristic clinical presentation. She was given oral isotretinoin and topical 20% acelaic acid cream twice a day and marked improvement was seen after 4 weeks.

Hidradenitis Suppurativa (HS) is an uncommon disease, which is particularly rare in young and prepubescent children. HS pathology centers on the follicular unit and involves aberrant cutaneous cellular immunity. HS tends to first manifest in puberty, but a handful of prepubescent cases of HS have been reported and are linked to hormonal disorders, in particular elevated testosterone. The most common manifestations of HS are abscesses, scarring, acne inversa, and keloids, especially in the intertriginous areas of the groin and the axilla. Treatments including topical anti-infectives including chlorhexidine wash, topical clindamycin, tretinoin cream, and azelaic acid cream, which may be of limited use because bacteria involved in HS likely create biofilms. Oral agents include clindamycin with or without rifampin for short-term usage. Cases resistant to conservative therapy have been reported to respond to finasteride, onabotulinumtoxin, or microfractionated 10,600-nm CO 2 laser. [ABSTRACT FROM AUTHOR]

Hidradenitis suppurativa (HS) is a chronic, debilitating skin disease characterized by painful recurrent nodules and abscesses. In advanced stages, sinus tracts form, with resulting fibrotic and cribriform scar formation, leading to dermal contractures and induration of the affected skin. The epidemiology of HS is poorly described, and few population-based studies exist. The reported incidence varies from 0.0003 to 4 %. Effective treatment options for HS are limited, and randomized controlled trials addressing the safety and/or efficacy of available treatments are scarce. No medical treatment to date has been approved by the US FDA specifically for the treatment of HS. While some evidence of disease improvement exists with agents including clindamycin and rifampicin, metformin, fumarates, infliximab, and adalimumab, no single treatment has shown overwhelmingly positive outcomes. The lack of randomized controlled trials for most treatments and often disappointing treatment outcomes is disheartening. This study reviews the published evidence for treatment options for HS. [ABSTRACT FROM AUTHOR]

Hidradenitis suppurativa/acne inversa ( HS) is a chronic, inflammatory, recurrent, debilitating skin disease of the hair follicle that usually presents after puberty with painful, deep-seated, inflamed lesions in the apocrine gland-bearing areas of the body, most commonly the axillae, inguinal and anogenital regions. A mean disease incidence of 6.0 per 100 000 person-years and an average prevalence of 1% has been reported in Europe. HS has the highest impact on patients' quality of life among all assessed dermatological diseases. HS is associated with a variety of concomitant and secondary diseases, such as obesity, metabolic syndrome, inflammatory bowel disease, e.g. Crohn's disease, spondyloarthropathy, follicular occlusion syndrome and other hyperergic diseases. The central pathogenic event in HS is believed to be the occlusion of the upper part of the hair follicle leading to a perifollicular lympho-histiocytic inflammation. A highly significant association between the prevalence of HS and current smoking (Odds ratio 12.55) and overweight (Odds ratio 1.1 for each body mass index unit) has been documented. The European S1 HS guideline suggests that the disease should be treated based on its individual subjective impact and objective severity. Locally recurring lesions can be treated by classical surgery or LASER techniques, whereas medical treatment either as monotherapy or in combination with radical surgery is more appropriate for widely spread lesions. Medical therapy may include antibiotics (clindamycin plus rifampicine, tetracyclines), acitretin and biologics (adalimumab, infliximab). A Hurley severity grade-relevant treatment of HS is recommended by the expert group following a treatment algorithm. Adjuvant measurements, such as pain management, treatment of superinfections, weight loss and tobacco abstinence have to be considered. [ABSTRACT FROM AUTHOR]

The article discusses the treatment of hidradenitis suppurativa with intralesional photodynamic therapy (PDT) by using a laser diode attached with an optical cable. Topics discussed include prevalence of HS in the patients with obesity and who use to smoke, use of intralesional 5-aminolaevulinic acid with use of PDT, and the randomized controlled trial will be the next step in the evaluation of therapeutic technique PDT.

Background Hidradenitis suppurativa ( HS), is a chronic, recurrent dermatosis affecting skin that contains apocrine glands. Photodynamic therapy using aminolaevulinic acid ( ALA) activated by intense pulsed light ( IPL) have shown variable success rates, with some adverse effects. Aims To evaluate the efficacy and safety of methylene blue ( MB) as a photosensitizer delivered as a niosomal gel for the treatment of HS using IPL. Methods We enrolled 11 patients with HS in the study, which was a randomized split-body study. One side of each patient's body was treated with niosomal MB ( NMB) gel and the other side was treated with unloaded (free) MB ( FMB) gel. The affected sites were irradiated using IPL with a 630 nm filter. Patients were followed up at 1, 3 and 6 months after treatment. Results Drug release from the FMB gel was significantly higher ( P > 0.05) than from the NMB gel. Lesions showed 77.3% and 44.1% reduction on the NMB and FMB sides, respectively. A significant reduction in the Hidradenitis Suppurativa Lesion, Area and Severity Index ( HS- LASI) after treatment was elicited in both groups, with no pain, erythema or hyperpigmentation. Conclusion The combination of MB as a photosensitizer activated with 630 nm IPL as a light source is a successful PDT for HS. Delivery of MB in niosomes was more effective for drug penetration to the dermis compared with delivery by FMB gel. The 630 nm filter was not only a source of activation of MB but also a means of hair-follicle destruction. [ABSTRACT FROM AUTHOR]

Background Hidradenitis suppurativa (HS) is an inflammatory skin disease with a chronic intermittent course. The current classification systems used to categorize disease severity provide limited insight into the degree of inflammation and pain, which are key symptoms of the disease. Objective We sought to investigate the correlation and validity of simple patient- and investigator-assessed items related to inflammation with morphological changes identified by high-frequency ultrasound in HS. Methods Twenty patients with the clinical diagnosis of HS were enrolled in this study. All patients underwent clinical examinations during which one representative inflammatory nodule was selected in each patient based on the anamnestic information, patient experience and clinical presentation. Tenderness and flare activity of the representative nodule were graded by the patients and erythema by the investigator. Subsequently, all patients underwent high-resolution ultrasound scanning of their representative nodule. Results We found significant associations between the size of the representative nodule (the diameter in the transverse plane) and patient assessments of flare activity and tenderness. Moreover, we found a marked association between the size of the nodules and investigator assessment of erythema. Conclusion Patient assessments of flare activity and pain, and investigator assessment of erythema are strongly associated with morphological changes identified using ultrasound, suggesting that these patient- and investigator-assessed items might be strong indicators of the degree of present inflammation in HS. [ABSTRACT FROM AUTHOR]

Background: Hidradenitis suppurativa (HS) is a chronic relapsing condition with a clinical picture that includes solitary nodules; diffuse, painful abscesses; malodorous drainage; sinus tract formation; and scarring. Treatment options are often unsatisfactory. The adverse effects of this disease on quality of life (QoL) is not extensively studied, especially in the Canadian population. Objectives: The objectives of this study were to (1) identify the impairment of QoL in patients with HS and the aspects that are most affected, and (2) assess the correlation between disease severity (based on Hurley's staging) and QoL impairment. Methods: This prospective case series studied 55 patients (38 females and 17 males) from community dermatology clinics in Ontario. All patients filled out the questionnaires for QoL data using the Dermatology Life Quality Index (DLQI) and the Short Form 36 Version 2 (SF-36v2) health survey, either in the clinic or over the telephone. Results: The mean DLQI score was 10 ± 8.8, indicating a moderate effect on patients' lives. In keeping with this, SF-36v2 scores were significantly reduced with respect to both physical and mental health. The severity of disease, as measured by Hurley staging, the number of lesions, and patient-reported QoL were significantly correlated with the DLQI score (β = 0.549, 0.285, 0.390, respectively; p = 0.000, 0.045, 0.004, respectively; α = 0.05). Conclusions: The impact on QoL for patients with HS is extensive yet underestimated; quantifying and assessing the burden of disease for the individual and society will lead to establishment of funding priorities and greater awareness of this condition. [ABSTRACT FROM AUTHOR]

Background Surgery is the only curative treatment for removal of the persistent sinus tracts in the skin that are characteristic of severe hidradenitis suppurativa ( HS). Complete resection of the affected tissue by wide excision is currently regarded as the preferred surgical technique in these cases. However, relatively large amounts of healthy tissue are removed with this method and suitable skin-tissue-saving techniques aiming at creating less-extensive surgical defects are therefore needed in severe HS. Method We describe a skin-tissue-saving surgical technique for HS Hurley stage II- III disease: the Skin-Tissue-sparing Excision with Electrosurgical Peeling ( STEEP) procedure. Discussion In contrast to wide excisions that generally reach into the deep subcutaneous fat, the fat is maximally spared with the STEEP procedure by performing successive tangential excisions of lesional tissue until the epithelialized bottom of the sinus tracts has been reached. From here, secondary intention healing can occur. In addition, fibrotic tissue is completely removed in the same manner as this also serves as a source of recurrence. This tissue-sparing technique results in low recurrence rates, high patient satisfaction with relatively short healing times and favourable cosmetic outcomes without contractures. [ABSTRACT FROM AUTHOR]

Background Hidradenitis suppurativa ( HS) is a chronic recurrent inflammatory disease affecting skin that bears apocrine glands. Only anecdotal reports and a few small studies have demonstrated a possible association between HS and depression, but these studies were uncontrolled or were based on small sample sizes. To the best of our knowledge, the association between HS and other psychiatric disorders has never been investigated. Objectives To investigate the association between HS and psychiatric disorders: depression, anxiety, psychoses, schizophrenia and bipolar disorder. Methods A cross-sectional study was conducted utilizing the database of Clalit Health Services (over 4 100 000 patients). Case patients were defined as having HS when diagnosed by a dermatologist. Control patients without HS were age and gender matched in a 2 : 1 manner. The proportions of patients with psychiatric diseases were compared between patients with and without HS. The association between HS and psychiatric diseases was assessed in multivariate models using logistic regression analyses. Results The study included 3207 patients with HS and 6412 age- and gender-matched controls. Depression was diagnosed in 5.9% of patients with HS vs. 3.5% of patients without HS ( P < 0.001). Anxiety was diagnosed in 3.9% of patients with HS vs. 2.4% of patients without HS ( P < 0.001). These associations were significant after controlling for the confounders age and gender (Depression: OR = 1.7, 95% CI: 1.4-2.1; Anxiety: OR = 1.7, 95% CI: 1.3-2.1). Conclusions Hidradenitis suppurativa was associated with depression and anxiety. Dermatologists treating patients with HS should be aware of this important association. [ABSTRACT FROM AUTHOR]

BACKGROUND. Hidradenitis suppurativa (HS) is a debilitating disease and is difficult to treat. Validation of surgical techniques is therefore of great importance in the management of HS. Carbon dioxide (CO2) laser evaporation has been shown effective, but larger-scale studies are scarce. OBJECTIVE. To determine the recurrence rate, time to recurrence, and factors influencing disease recurrence in skin treated with CO2 laser evaporation, and healing by secondary intention; and patients’ satisfaction with treatment. METHODS. Fifty-eight patients treated with CO2 laser evaporation were interviewed regarding recurrence and satisfaction after a mean of 25.7 months. RESULTS. Seventeen of 58 (29%) reported recurrence of HS lesions within the borders of the treated areas after a mean of 12.7 months. Obesity was a risk factor for recurrence with a hazard ratio of 4.53. Fifty-five patients (95%) reported some or great improvement, and 91% would recommend the CO2 laser surgery to other HS patients. CONCLUSION. This study supports the claim that CO2 laser treatment is an effective modality for recurrent HS lesions in a majority of patients. The authors identified obesity as a risk factor for recurrence. Self-reported satisfaction is high, and only 3 of 58 report no change in the condition. None reported a worsening. [ABSTRACT FROM AUTHOR]

Neutrophilic eccrine hidradenitis (NEH) is a dermatosis affecting the eccrine glands in particular characterized by acute, self-limited, inflammatory papules and plaques and has been commonly described in patients with cancer - particularly acute myeloid leukemia (AML) - who are on chemotherapy. We present the case of a febrile neutropenic patient receiving chemotherapy for AML and presented with well-defined erythematous macules and papule suggestive of NEH. This report emphasizes the necessity of a prompt diagnosis in order to prevent the use of multiple antibiotics and inadvertent use of other drugs as it is a self-limiting condition. [ABSTRACT FROM AUTHOR]

A 14-year-old boy who had undergone a matched sibling bone marrow transplant for acute lymphoblastic leukemia presented with painful nodules on his palms after prolonged gaming on his computer and mobile phone. Histology showed a neutrophilic inflammatory infiltrate surrounding the acrosyringium and eccrine sweat coils in the deep dermis. The lesions resolved spontaneously with conservative management. [ABSTRACT FROM AUTHOR]

The aetiopathogenesis of hidradenitis suppurativa ( HS) is not fully understood; however, increasing evidence suggests that it may be an immune-mediated disorder. Autoimmune thyroid disease ( AITD) has classically been considered as the 'paradigm' of autoimmunity, and it has been linked to a variety of skin disorders. To our knowledge, the prevalence of AITD has not been investigated in patients with HS. The aim of the present study was to assess and compare, for the first time, the prevalence of thyroid autoimmunity in 70 patients with HS and in 70 age- and sex-matched controls. In all participants, thyroid autoantibodies and thyroid function tests were analysed. No statistically significant difference was detected between patients with HS and controls, either for the prevalence of thyroid antibodies or for thyroid function parameters. This lack of an association between HS and thyroid autoimmunity suggests that conventional autoimmune mechanisms may not be implicated in the pathogenesis of HS. [ABSTRACT FROM AUTHOR]